Sign inJoin waitlistJoin the waitlist

John Koreth

Director of Translational Research, Stem Cell Transplantation · Mass General Brigham

Credentials: · · ·

History

Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2004–2007
G.B. Pant Hospital
2000–2004
G.B. Pant Hospital
1996–2000
Internal Medicine
Brigham and Women's Hospital
1993–1996
Oxford University
MAULANA AZAD MED COLL, DELHI UNIV, NEW DELHI, DELHI
1989–1993

Research

Interleukin-2 and regulatory T cells in graft-versus-host disease
New England Journal of Medicine · 2011 · First of 18 authors · Corresponding · 929 citations
Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNAi library
Genome Research · 2004 · 760 citations
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
Systematic review or meta-analysis · JAMA · 2009 · First of 15 authors · Corresponding · 708 citations

Robert Soiffer
150 papers
Corey Cutler
148 papers
Joseph Antin
147 papers
Vincent Ho
133 papers
Jerome Ritz
103 papers
Edwin Alyea
102 papers
Philippe Armand
78 papers · 1 as a fellow
Sarah Nikiforow
62 papers
Mahasweta Gooptu
41 papers · 6 as a fellow
Rizwan Romee
37 papers
Bruce Blazar
28 papers
Roman Shapiro
27 papers

Clinical trials

IS-free Treg HaploHCT
Principal investigator · Recruiting · Phase 1
Dana-Farber Cancer Institute
2021–2029
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
2019–2026
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2015–2020
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2015–2025